ASTRAZENECA PLC

Discover how AstraZeneca’s $10 billion proposal to acquire Rhythm Pharmaceuticals could fast‑track rare‑disease treatments, boost its portfolio, and transform patient access to obesity and neuro‑endocrine therapies.

Discover why AstraZeneca’s Q2 earnings beat the market, the drivers behind its oncology and rare‑disease growth, and the risks and opportunities shaping its future.

Discover how AstraZeneca’s oncology surge and late‑stage pipeline are driving growth, outpacing tech and banking volatility.

Discover how AstraZeneca’s new sone‑ve therapy cuts gastric‑cancer deaths by 53%, offers a safer profile, and may reshape pricing, reimbursement, and hospital delivery strategies.

Imfinzi’s phase‑III trials show a 8‑month OS boost in extensive‑stage small cell lung cancer and improved peri‑operative survival in muscle‑invasive bladder cancer when paired with bispecific T‑cell engagers or enfortumab‑vedotin, with manageable sa…

Explore AstraZeneca’s modest share rise amid AI, oil, and consumer headwinds, and how its clinical pipeline and regulatory milestones shape investor sentiment.

Discover how AstraZeneca’s AI‑driven investment accelerates new anticancer drugs from lab to clinic, boosting pipeline speed and precision.

How AstraZeneca’s London dip reflects broader macro‑policy worries and hidden growth opportunities in pharma, beyond short‑term market swings.